Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
The purpose of our study was to determine the efficacy of 2-chlorodeoxyadenosine (2-CdA) administered in 2-hour intravenous infusions in previously treated patients with low grade non-Hodgkin's lymphoma (LGNHL). We treated 94 LGNHL patients with 2-CdA at a dosage of 0.12 mg/kg/24h in 2-hour intravenous infusion for 5 consecutive days. The treatment consisted of from 1 to 7 courses (median 3), repeated usually at monthly intervals. All patients were refractory to or relapsed after standard chemotherapy. Of these 94 patients 78 (83%) had clinical stage IV of the disease. Complete response (CR) was obtained in 12 (12.8%) and partial response (PR) in 36 (38.3%) giving an overall response rate of 51.1%. In 12 (12.8%) grade 4 thrombocytopenia with haemorrhagic diathesis was noted, grade 4 neutropenia was observed in 12 (12.8%) and infections complicated the course of treatment in 38 (40.4%) patients. 2-CdA treatment was the cause of death of 3 patients. The results of our study show that 2-CdA given in 2-hour infusions is an effective agent in advanced, heavily pretreated patients with LGNHL.
Róbak
T
T
Department of Hematology, Medical University of Lódź, Poland.
Gora-Tybor
J
J
Krykowski
E
E
Walewski
J A
JA
Borawska
A
A
Pluźańska
A
A
Potemski
P
P
Hellmann
A
A
Zaucha
J M
JM
Konopka
L
L
Ceglarek
B
B
Durźyński
T
T
Sikorska
A
A
Michalak
K
K
Urasiński
J
J
Opalińska
J
J
Dmoszyńska
A
A
Adamczyk-Cioch
M B
MB
Kuratowska
Z
Z
Dwilewicz-Trojaczek
J
J
Boguradzki
P
P
Deren
M
M
Maj
S
S
Grieb
P
P
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019233:Retreatment
D000970:Antineoplastic Agents; D017338:Cladribine